People · Operator
Named in public records as an officer, director or promoter · active 2018–2020 · Pharmaceuticals, Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Olema Pharmaceuticals, Inc. | — | Pharmaceuticals | Series D+ | $527.4M | $2.4B | 2020 |
| Akero Therapeutics, Inc. | — | Pharma | Series C | $45.5M | $1.6B | 2018 |
Graham Walmsley at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Graham Walmsley on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kevin Bitterman | 1 | 15 |
| Frank McCormick | 1 | 7 |
| Aaron Royston | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Ian Clark | 1 | 5 |
| Mark Iwicki | 1 | 4 |
| Marina Bozilenko | 1 | 3 |
| Gorjan Hrustanovic | 1 | 3 |
| Cynthia Butitta | 1 | 3 |
| Sean Bohen | 1 | 2 |
| David Myles | 1 | 2 |
| Andrew Rappaport | 1 | 2 |
| Cyrus Harmon | 1 | 2 |
| Andrei Manoliu | 1 | 2 |
| Lawrence Fritz | 1 | 2 |
| Andrew Cheng | 1 | 2 |
| Shane Kovacs | 1 | 1 |
| John Moriarty | 1 | 1 |
| Pamela Klein | 1 | 1 |
| Gorjan Hrustanovich | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.